

# Institutional review board statement

This study was reviewed and approved through the National Cheng Kung University Hospital Institutional Review Board.

文件編號：8800-4-07-001

B010th

Institutional Review Board  
National Cheng Kung University Hospital  
138 Sheng-Li Rd. Tainan 704, Taiwan R.O.C.  
TEL:886-6-2353535 ext.4826 FAX:886-6-2388190

國立成功大學醫學院附設醫院  
第二人體試驗委員會  
台灣,台南市勝利路138號  
E-mail:n955979@mail.hosp.ncku.edu.tw

## 同意人體研究證明書

計畫名稱：微小 RNA 106b, 93, 25, let-7c, 99a, 100 調控並促進肝癌進展機制探討

計畫編號/本會編號：--/ B-ER-101-151

內容/版本：

1.計畫書：版本：Version 1，日期：2012/7/19

2.以之前所申請計畫所收集之剩餘檢體進行探討 Micro-RNA-106b, 93, 25 let-7c, 99a, 100 是否可促進並參與肝癌的發展，並進一步研究其詳細作用機制：免除受試者同意

下次繳交報告日期：民國 102 年 09 月 30 日

試驗機構：成大醫院

計畫主持人：顏家瑞 醫師(內科部)

共同主持人：沈延盛 醫師

協同研究員：顏家聖 醫師

此計畫已於民國 101 年 09 月 06 日本院人體試驗委員會審核通過，本會組織與執行皆遵照 ICH-GCP 規範，有效執行期限民國 101 年 09 月 06 日至民國 104 年 07 月 31 日，特此證明。計畫主持人若未依規定於執行期限到期後三個月內繳交報告者，本會將保留審核權。若有任何不良反應亦須依藥品優良臨床試驗準則(GCP)通報；該計畫任何部份若欲更改，請於有效期限內向本會提出申請。

中 華 民 國 101 年 09 月 12 日

## Human Study Approval

Date: 12. Sep, 2012

Title: Explore the mechanism of Micro-RNA-106b, 93, 25, let-7c, 99a, 100 regulates cell cycle and promotes hepatocellular carcinoma progression

Protocol No/ IRB No: --/ B-ER-101-151

Content/Version:

1. Protocol: Version: 1, Date: 2012/7/19

2. Waive Informed Consent: Using Remaining Specimen

Next Hand-in Report Date: Sep. 30, 2013

Institute: Department of Internal Medicine, National Cheng Kung University Hospital

Investigator: Dr. Yen Chia-Jui

Co-Investigator: Dr. Shan Yan-Shen

Co-Researcher: Dr. Yen Chia-Shang

This is a certification to show that the protocol has been approved by Institutional Review Board (IRB) on Sep. 06, 2012, and the valid execution date is from Sep. 06, 2012 to Jul. 31, 2015. The Institutional Review Board of National Cheng Kung University Hospital (NCKUH) is organized and operated according to the laws and regulations of ICH-GCP. For those principal investigators who are 3 months late in submitting the final reports, the NCKUH IRB will retain the review rights. If any Adverse Event occurs, the IRB should be notified as required by GCP. If any part of the protocol needs to be altered, please submit the application to NCKUH IRB within the valid execution date.

Your sincerely,  
Chyun-Yu Yang M.D.  
Chairman



Institutional Review Board  
National Cheng Kung University Hospital